Department of Neurodegeneration Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland.
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, 405 30 Gothenburg, Sweden.
Int J Mol Sci. 2023 Aug 24;24(17):13166. doi: 10.3390/ijms241713166.
In addition to amyloid and tau pathology in the central nervous system (CNS), inflammatory processes and synaptic dysfunction are highly important mechanisms involved in the development and progression of dementia diseases. In the present study, we conducted a comparative analysis of selected pro-inflammatory proteins in the CNS with proteins reflecting synaptic damage and core biomarkers in mild cognitive impairment (MCI) and early Alzheimer's disease (AD). To our knowledge, no studies have yet compared CXCL12 and CX3CL1 with markers of synaptic disturbance in cerebrospinal fluid (CSF) in the early stages of dementia. The quantitative assessment of selected proteins in the CSF of patients with MCI, AD, and non-demented controls (CTRL) was performed using immunoassays (single- and multiplex techniques). In this study, increased CSF concentration of CX3CL1 in MCI and AD patients correlated positively with neurogranin (r = 0.74; < 0.001, and r = 0.40; = 0.020, respectively), ptau181 (r = 0.49; = 0.040), and YKL-40 (r = 0.47; = 0.050) in MCI subjects. In addition, elevated CSF levels of CXCL12 in the AD group were significantly associated with mini-mental state examination score (r = -0.32; = 0.040). We found significant evidence to support an association between CX3CL1 and neurogranin, already in the early stages of cognitive decline. Furthermore, our findings indicate that CXCL12 might be a useful marker for tract severity of cognitive impairment.
除了中枢神经系统(CNS)中的淀粉样蛋白和tau 病理学,炎症过程和突触功能障碍也是痴呆疾病发展和进展中非常重要的机制。在本研究中,我们对 CNS 中的选定促炎蛋白与反映突触损伤的蛋白以及轻度认知障碍(MCI)和早期阿尔茨海默病(AD)中的核心生物标志物进行了比较分析。据我们所知,尚无研究比较过 CSF 中 CXCL12 和 CX3CL1 与突触紊乱标志物在痴呆早期的相关性。使用免疫测定法(单重和多重技术)对 MCI、AD 和非痴呆对照(CTRL)患者 CSF 中的选定蛋白进行了定量评估。在这项研究中,MCI 和 AD 患者 CSF 中 CX3CL1 浓度增加与神经颗粒蛋白(r = 0.74; < 0.001,r = 0.40; = 0.020)呈正相关,与 ptau181(r = 0.49; = 0.040)和 YKL-40(r = 0.47; = 0.050)在 MCI 患者中呈正相关。此外,AD 组 CSF 中 CXCL12 水平升高与简易精神状态检查评分呈显著负相关(r = -0.32; = 0.040)。我们有充分的证据表明 CX3CL1 与神经颗粒蛋白之间存在关联,这在认知能力下降的早期阶段就已经存在。此外,我们的研究结果表明,CXCL12 可能是认知障碍严重程度的有用标志物。